PMID- 36440887
OWN - NLM
STAT- MEDLINE
DCOM- 20230707
LR  - 20230718
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 62
IP  - 7
DP  - 2023 Jul 5
TI  - Therapeutic consequences in patients with both inflammatory rheumatic diseases 
      and multiple sclerosis.
PG  - 2352-2359
LID - 10.1093/rheumatology/keac665 [doi]
AB  - Dealing with patients with both multiple sclerosis (MS) and inflammatory 
      rheumatic disorders (IRDs) is not uncommon for a rheumatologist, as there is a 
      statistical association between SpA and MS. As several CNS demyelinating events 
      have been reported in patients treated with TNF inhibitor (TNFi), the 
      pre-existing demyelinating disease was considered a contraindication for TNFi. 
      However, this contraindication is mainly based on a randomized controlled trial 
      in MS and not on large epidemiological studies. According to the last 
      epidemiological studies, TNFi might not be an inducer of MS. Moreover, there are 
      no clear recommendations on the use of the other DMARDs in patients suffering 
      from an IRD and MS. In this review, we summarize the link between MS and IRDs and 
      the impact of DMARDs on MS, especially TNFi. We also look at the impact of 
      disease-modifying drugs for adults with MS and IRDs.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology. All rights reserved. For permissions, please 
      email: journals.permissions@oup.com.
FAU - Letarouilly, Jean-Guillaume
AU  - Letarouilly JG
AUID- ORCID: 0000-0003-2793-6303
AD  - Universite de Lille, CHU Lille, FHU PRECISE, Service de Rhumatologie, Lille, 
      France.
FAU - Vermersch, Patrick
AU  - Vermersch P
AUID- ORCID: 0000-0003-0997-8817
AD  - Universite de Lille, CHU Lille, INSERM UMR1172 LilNCog, FHU PRECISE, Service de 
      Neurologie, Lille, France.
FAU - Flipo, Rene-Marc
AU  - Flipo RM
AUID- ORCID: 0000-0001-5528-8070
AD  - Universite de Lille, CHU Lille, FHU PRECISE, Service de Rhumatologie, Lille, 
      France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - *Multiple Sclerosis/drug therapy
MH  - Tumor Necrosis Factor-alpha
MH  - *Antirheumatic Agents/therapeutic use
MH  - *Rheumatic Fever/drug therapy
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - PsA
OT  - RA
OT  - TNF inhibitor
OT  - bDMARD
OT  - multiple sclerosis
OT  - spondyloarthritis
EDAT- 2022/11/29 06:00
MHDA- 2023/07/07 06:42
CRDT- 2022/11/28 08:25
PHST- 2022/08/10 00:00 [received]
PHST- 2022/11/19 00:00 [accepted]
PHST- 2023/07/07 06:42 [medline]
PHST- 2022/11/29 06:00 [pubmed]
PHST- 2022/11/28 08:25 [entrez]
AID - 6849504 [pii]
AID - 10.1093/rheumatology/keac665 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2023 Jul 5;62(7):2352-2359. doi: 
      10.1093/rheumatology/keac665.